{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:57:14Z","timestamp":1770818234354,"version":"3.50.1"},"reference-count":46,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1419,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1111\/j.1600-0404.2011.01594.x","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T05:27:20Z","timestamp":1318483640000},"page":"37-44","source":"Crossref","is-referenced-by-count":9,"title":["Two galantamine titration regimens in patients switched from donepezil"],"prefix":"10.1155","volume":"126","author":[{"given":"K.","family":"Engedal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Richarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sch\u00e4uble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2011,10,13]]},"reference":[{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB1|cit1","volume-title":"Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer\u2019s disease (amended)","author":"NICE","year":"2007"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB2|cit2","unstructured":"D eutsche G esellschaft f\u00fcr P sychiatrie P sychotherapie und N ervenheilkunde (DGPPN), D eutsche G esellschaft f\u00fcr N eurologie (DGN) 2009 http:\/\/www.dgn.org\/images\/stories\/dgn\/leitlinien\/ll_demenz\/ll-demenz-kurz-170210.pdf"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB3|cit3","volume-title":"Nationella riktlinjer f\u00f6r v\u00e5rd och omsorg vid demenssjukdom 2010 - st\u00f6d f\u00f6r styrning och ledning","author":"Socialstyrelsen","year":"2010"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB4|cit4","volume-title":"Practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias","author":"American Psychiatric Association","year":"2007"},{"issue":"1","key":"10.1111\/j.1600-0404.2011.01594.x-BIB5|cit5","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"25","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/11318010-000000000-00000","article-title":"Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer\u2019s disease: a 2-year prospective, multicentre, cohort study","volume":"24","author":"Gardette","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.18553\/jmcp.2005.11.3.231","article-title":"Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings","volume":"11","author":"Mauskopf","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00002512-200522080-00006","article-title":"Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer\u2019s disease","volume":"22","author":"Suh","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.18553\/jmcp.2008.14.5.462","article-title":"Cholinesterase inhibitor utilization patterns: just because it can be counted does not mean it counts","volume":"14","author":"Starner","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1185\/030079903125002450","article-title":"Strategies for continued successful treatment of Alzheimer\u2019s disease: switching cholinesterase inhibitors","volume":"19","author":"Gauthier","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1185\/030079905X65655","article-title":"Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer\u2019s disease","volume":"21","author":"Bartorelli","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/j.1532-5415.2004.52529_3.x","article-title":"Switching from donepezil or rivastigmine to galantamine in clinical practice","volume":"52","author":"Edwards","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB13|cit13","first-page":"64","article-title":"Switching cholinesterase inhibitors in patients with Alzheimer\u2019s disease","volume":"127","author":"Emre","year":"2002","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","article-title":"MRI and CSF biomarkers in normal, MCI and AD subjects. Predicting future clinical change","volume":"73","author":"Vemuri","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1600-0404.2010.01435.x","article-title":"Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer\u2019s disease","volume":"124","author":"Parnetti","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/gps.1301","article-title":"Switching from donepezil to galantamine: a double-blind study of two wash-out periods","volume":"20","author":"Wilkinson","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"issue":"Suppl. A","key":"10.1111\/j.1600-0404.2011.01594.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/S0149-2918(01)80162-4","article-title":"Switching previous therapies for Alzheimer\u2019s disease to galantamine","volume":"23","author":"Ferris","year":"2001","journal-title":"Clin Ther"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB21|cit21","first-page":"448","article-title":"The Alzheimer\u2019s disease assessment scale: an instrument for assessing treatment efficacy","volume":"19","author":"Mohs","year":"1983","journal-title":"Psychopharmacol Bull"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0404.2009.01160.x","article-title":"The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer\u2019s disease","volume":"121","author":"Wiig","year":"2010","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 2","key":"10.1111\/j.1600-0404.2011.01594.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer\u2019s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Suppl. 2","key":"10.1111\/j.1600-0404.2011.01594.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB26|cit26","first-page":"pii:PCC.09m0085","article-title":"Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer\u2019s disease: 20-week extension phase results","volume":"12","author":"Sadowsky","year":"2010","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1176\/ajp.151.3.390","article-title":"A longitudinal study of Alzheimer\u2019s disease: measurement, rate, and predictors of cognitive deterioration","volume":"151","author":"Stern","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"Suppl. A","key":"10.1111\/j.1600-0404.2011.01594.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1016\/S0149-2918(01)80163-6","article-title":"Pharmacokinetic rationale for switching from donepezil to galantamine","volume":"23","author":"Maelicke","year":"2001","journal-title":"Clin Ther"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer\u2019s disease - results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/gps.1746","article-title":"Efficacy and safety of donepezil over 3\u2003years: an open-label, multicentre study in patients with Alzheimer\u2019s disease","volume":"22","author":"Burns","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","author":"Doody","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1527-3458.2001.tb00204.x","article-title":"Donepezil for Alzheimer\u2019s disease: pharmacodynamic, pharmacokinetic, and clinical profiles","volume":"7","author":"Shigeta","year":"2001","journal-title":"CNS Drug Rev"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1365-2389.2003.51306.x","article-title":"Donepezil is associated with delayed nursing home placement in patients with Alzheimer\u2019s disease","volume":"51","author":"Geldmacher","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer\u2019s disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cbi.2008.04.047","article-title":"Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer\u2019s cerebrospinal fluid","volume":"175","author":"Garcia-Ayll\u00f3n","year":"2008","journal-title":"Chem Biol Interact"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1358\/dot.2003.39.1.740206","article-title":"The role of acetylcholinesterase in the pathogenesis of Alzheimer\u2019s disease","volume":"39","author":"Rees","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1432-1327.1999.00693.x","article-title":"Structural roles of acetylcholinesterase variants in biology and pathology","volume":"264","author":"Grisaru","year":"1999","journal-title":"Eur J Biochem"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1248\/bpb.32.332","article-title":"Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models","volume":"32","author":"Shimohama","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/mol.108.046789","article-title":"Roles of accessory subunits in alpha4beta2(*) nicotinic receptors","volume":"74","author":"Kuryatov","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer\u2019s disease: a randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer\u2019s disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2011.01594.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1185\/030079905X61965","article-title":"Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers","volume":"21","author":"Zhao","year":"2005","journal-title":"Curr Med Res Opin"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2011.01594.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2011.01594.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:50:14Z","timestamp":1671540614000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2011.01594.x"}},"subtitle":["Galantamine in patients switched from donepezil"],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2011.01594.x","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}